Shares of Trevena (TRVN) came back to life. The struggling biotech stock took a rare leap upward last week, as well as today, as resolution …
It’s a very rewarding trading day for investors in Trevena (TRVN) with shares up over 70%, making the stock Wall Street’s bull of …
On Friday, Trevena (TRVN) announced it received a discouraging Complete Response Letter (CRL) from the FDA for its experimental pain drug, Oliceridine. Importantly, …
Some investors might love biotech stocks for their lottery ticket-like returns when a company wins the regulator’s blessing. A lottery ticket, however, costs only …
In a research note issued today, healthcare analyst Alan Carr of Needham walks investors through this week’s Trevena (TRVN) bloodbath. Shares are down nearly over …
Tuesday turned out to be a nightmare for shareholders of Trevena (TRVN), as the stock price plummeted 64% in the wake of negative …
The Food and Drug Administration (FDA) is scheduled to hold an advisory committee meeting on Friday to review AcelRx’s (ACRX) pain medication Dsuvia. …
The US Food and Drug Administration (FDA) puts the needle in the arm of drug company Trevena (TRVN). The agency’s critical briefing documents …
Every month brings plenty of catalysts for several biotech stocks. October is no exception.
JMP analysts have profiled two biopharmaceutical firms that they believe are set up to do well in the rest of 2018 and beyond. Both companies are …
